Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

Table 2 Univariate associations of baseline variables with successful TNFi discontinuation

Predictor	OR	95% CI	P
anti-TNF monoclonal antibody^a	2.26	1.53–3.34	< 0.0001
Concomitant DMARD	1.21	0.51–2.85	0.670
Female sex	1.07	0.72–1.60	0.735
Younger age (≤60 yrs.)	1.17	0.80–1.70	0.417
Shorter disease duration (≤10 yrs.)	2.00	1.34–2.98	0.001
RF negative	1.14	0.75–1.74	0.530
ACPA negative	1.06	0.70–1.62	0.775
Non-erosive	1.62	1.08–2.44	0.020
Normal weight (BMI 18.5–25)	1.35	0.92–1.98	0.128
First TNFi	1.23	0.71–2.13	0.461
DAS28 deep remission (DAS28 ≤ 1.98)	1.21	0.83–1.77	0.314
Low or moderate MBDA (≤44)	2.32	1.32–4.05	0.003

^aReference category is receptor antagonist
TNFi tumor necrosis factor-alpha inhibitors, csDMARD conventional synthetic disease modifying anti-rheumatic drug, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide, BMI body mass index, DAS28 disease activity score in 28 joints, MBDA multi-biomarker disease activity

ISSN: 2520-1026